Faster pipeline progression is discussed by Catalent expert at European Antibody Congress 2012

Somerset, NJ, November 26, 2012 – Greg Bleck, Ph.D., R&D Platform Director-Biologics, Catalent Pharma Solutions, will participate in a panel discussion titled “How collaboration can lead to faster pipeline progression,” onWednesday, November 28, 2012 at the European Antibody Congress 2012 at the Starling Geneva Hotel & Conference Center, Geneva, Switzerland.

This content was submitted directly to this website by the supplier.

Part of the event’s Monoclonal Antibody Track, the panel discussion will follow the presentation of a partnership case study on Pritumumab by Mark Glassy, Chief Executive Officer of Nascent Biologics, Inc., and will examine how the collaboration was established and the skill set brought by each company. The session will go on to discuss the benefits of developing pipelines in this manner, factoring on timescales, cost and scientific expertise. It will conclude by looking to the future and how such relationships can help to take more products through the clinic to the market.

Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics. He has a broad background in molecular biology, mammalian geneexpression, cell culture and transgenic animals. Dr. Bleck holds a Bachelor’s degree in Dairy Science and has a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison.  He performed postdoctoral work at the University of Illinois-Urbana, working in the areas of gene regulation and expression. Dr. Bleck has published more than 55 research papers and co-authored three bookchapters.

Companies in this article
More in Home